Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue

 Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue

Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue

Shots:
  • Instituto Butantan to receive $26M upfront, $75M milestones and royalties on sales from Merck. Merck to get clinical data and learnings (utilized for its TV003, dengue vaccine) from Instituto’s development programs to develop vaccines for dengue
  • The focus of the agreement is to develop live attenuated tetravalent vaccines (LATV) against the dengue virus for patients suffering in Brazil
  • TV003 is a LATV P-III candidate, assessing 17,000 healthy people aged 2 to 59 years in 15 cities, indicated to treat dengue infection

Click here to read full press release/ article | Ref: Merck | Image: Endpoint News

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post